Glimisave M4 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 4mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination offers complementary mechanisms of action, providing improved glycemic control compared to monotherapy. Glimisave M4 Forte Tablet PR is typically prescribed when diet, exercise, and monotherapy do not achieve adequate glycemic control. It is important to monitor blood glucose levels regularly and assess renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Hypoglycemia risk is primarily associated with Glimepiride, necessitating patient education on recognizing and managing low blood sugar episodes. This medication should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability. Glimisave M4 Forte Tablet PR contributes effectively to comprehensive diabetes management when combined with lifestyle modifications.